PMID: 11934561Apr 6, 2002Paper

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA

FEMS Immunology and Medical Microbiology
M J McCluskieH L Davis

Abstract

Synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG ODN) are potent adjuvants to protein antigens administered by parenteral or mucosal routes to BALB/c mice. To date, there have been no studies using combined parenteral/mucosal approaches with CpG DNA as adjuvant. In this study we evaluated different parenteral prime-mucosal boost and mucosal prime-parenteral boost strategies using hepatitis B surface antigen (HBsAg) alone or with different adjuvants: aluminum hydroxide (alum), cholera toxin (CT), CpG ODN. In addition, since CpG ODN has previously been shown to act synergistically with other adjuvants after parenteral or mucosal delivery, we also evaluated adjuvant combinations: alum+CpG ODN and CT+CpG ODN. The effects of adjuvant and administration strategy on systemic and mucosal humoral responses were measured, as well as cell-mediated immune responses (cytotoxic T lymphocyte activity). These results were compared to parenteral only or mucosal only strategies. Our findings demonstrate that parenteral immunization can prime for mucosal responses even when different lymph nodes were being targeted. HBsAg-specific immune responses (IgG in plasma, cytotoxic T lymphocytes) induced by parenteral pri...Continue Reading

References

Jan 1, 1995·The Journal of Infectious Diseases·K A BrokstadL R Haaheim
Aug 15, 1994·Annals of the New York Academy of Sciences·R A Daynes, B A Araneo
Sep 25, 1997·Clinical and Diagnostic Laboratory Immunology·M M HerremansM P Koopmans
Oct 3, 1999·Vaccine·M J McCluskie, H L Davis
Dec 1, 1999·Inflammatory Bowel Diseases·S Romagnani
Dec 2, 1999·Immunologic Research·V K SinghS S Agarwal
Jun 29, 2000·Immunology Today·M P DavenportA R Lloyd
Mar 17, 2001·Intervirology·R D WeeratnaH L Davis

❮ Previous
Next ❯

Citations

Apr 15, 2004·Experimental Neurology·Douglas R MartinHenry J Baker
Sep 10, 2010·Journal of Virology·Helga Hofmann-SieberRalf Wagner
Jul 16, 2005·Expert Opinion on Biological Therapy·Michael Vajdy, Manmohan Singh
Jan 16, 2013·Clinical & Developmental Immunology·Aziz Alami Chentoufi, Lbachir Benmohamed
Mar 21, 2008·Molecular Genetics and Metabolism·Douglas R MartinHenry J Baker
Jul 31, 2007·Biochemical and Biophysical Research Communications·Rui MaChang-you Wu
Apr 14, 2004·Critical Reviews in Clinical Laboratory Sciences·Sharmila ManojSylvia van Drunen Littel-van den Hurk
Oct 18, 2005·The Journal of General Virology·M Magdalena Gherardi, Mariano Esteban
Sep 10, 2014·Frontiers in Microbiology·Beatrice O Ondondo
Mar 19, 2008·Animal Health Research Reviews·Mahendrasingh RamjeetMario Jacques
Nov 20, 2010·Pharmaceutical Research·Filipa LebreOlga Borges
Dec 12, 2007·Journal of Leukocyte Biology·Alan S CrossMyron M Levine
Dec 3, 2009·Pharmaceutical Research·Olga BorgesHans E Junginger
Jan 21, 2021·Frontiers in Cell and Developmental Biology·Lin CuiDekai Zhang
Jun 15, 2004·Vaccine·Charalambos D PartidosSylviane Muller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.